Song Jiang Ma
Chief Executive Officer at Continent Pharmaceutical Inc.
Profile
Song Jiang Ma is the founder of Beijing Kangdini Factory, which was founded in 1996.
He held the title of General Manager at the company.
Currently, Mr. Ma holds several positions.
He is the Chief Executive Officer & Executive Director at Continent Pharmaceutical Inc. since 2002.
He is also the General Manager & Executive Director at Beijing Continent Pharmaceutical Co., Ltd.
since 2002.
Additionally, he is an Executive Director & Manager at Beijing Jisheng Connor Network Technology Co. Ltd.
and the President & Director at Gyre Therapeutics, Inc. since 2023.
In the past, Mr. Ma served as the President & Director at Catalyst Biosciences, Inc. He was also a Director at Beijing Institute of Telecommunication & Computer Applications and Beijing Jisheng Kangning Medical Technology Development.
Furthermore, he worked as a Supervisor at Beijing Kangqiang Economic & Technical Co. Ltd.Mr. Ma's education includes an undergraduate degree from Beijing University of Posts & Telecommunications.
He also obtained a graduate degree from China Electric Power Research Institute Ltd.
in 1983.
Song Jiang Ma active positions
| Companies | Position | Start |
|---|---|---|
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Chief Executive Officer | 2002-06-30 |
| Beijing Jisheng Connor Network Technology Co. Ltd. | Director/Board Member | - |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Chief Executive Officer | 2011-06-30 |
Former positions of Song Jiang Ma
| Companies | Position | End |
|---|---|---|
| CATALYST BIOSCIENCES | President | - |
| Beijing Kangdini Factory | Founder | - |
| Beijing Jisheng Kangning Medical Technology Development | Director/Board Member | - |
| Beijing Kangqiang Economic & Technical Co. Ltd. | Director/Board Member | - |
| Beijing Institute of Telecommunication & Computer Applications | Director/Board Member | - |
Training of Song Jiang Ma
| China Electric Power Research Institute Ltd. | Graduate Degree |
| Beijing University of Posts & Telecommunications | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
| Beijing Jisheng Connor Network Technology Co. Ltd. | |
| Beijing Institute of Telecommunication & Computer Applications | |
| Beijing Jisheng Kangning Medical Technology Development | |
| Beijing Kangqiang Economic & Technical Co. Ltd. | |
| Beijing Kangdini Factory | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Song Jiang Ma
